Previous 10 |
home / stock / sphry / sphry news
Starpharma VivaGel antiviral condom launched in Japan under Okamoto 003 brand Last month I wrote an article suggesting that Starpharma’s (OTCQX: OTCQX:SPHRY ) share price has been savaged by COVID-19 for no good reason. Now Starpharma is showing signs of fighting back against ...
Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-2 1 (coronavirus), which causes COVID-19 SPL7013 is the active component in Starpharma’s range of marketed VivaGel ® products 2 (VivaGel ® BV and th...
The coronavirus crisis has no respect, so almost all stocks are down. Of course, we still don't know how severe or prolonged this crisis will turn out to be, but it is also clear that as the initial sharp drop starts to level off, there will be opportunity, especially for companies that are we...
AstraZeneca has commenced its first-in-human/phase 1 clinical trial for AZD0466 in the US in a range of cancers AZD0466 utilises Starpharma’s proprietary DEP ® delivery technology and is a highly optimised nanomedicine formulation of a novel dual Bcl2/xL inhibitor ...
Source: Starpharma Investment in emerging biotech companies is a black art, usually full of obvious risk, and every result needs to be a good one. Cash is usually a big issue. I'm a long term investor in Starpharma (OCTQX:SPHRY) and recently published an article with a list of good news st...
I’m embarrassed to admit when I first invested in Starpharma (SPHRY), or SPL on the ASX). Let’s just say it was a long time ago. Over the years, I’ve done well selling shares when they were in vogue and buying when they were unloved. Throughout the last decade, common th...
Starpharma has signed a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP ® ) version of one of AstraZeneca’s major marketed oncology medicines. Following completion of agreed preclinical studies by Sta...
News, Short Squeeze, Breakout and More Instantly...
Starpharma Hldgs S/Adr Company Name:
SPHRY Stock Symbol:
OTCMKTS Market:
Uni Charm Corporation ADR (UNICY) is expected to report for Q2 2023 Clarus Therapeutics Hldgs (CRXTQ) is expected to report for quarter end 2023-06-30 Bed Bath & Beyond Inc. (BBBYQ) is expected to report for Q2 2024 CalAmp Corp. (CAMP) is expected to report $-0.04 for Q2 2024 ...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-06-30 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Arrival (ARVL) is expected to report for quarter end 2023-06-30 Treasure Global Inc. (TGL) is expected to report $-0.16 for Q4 2023 Manch...
Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...